3160 PORTER DR., PALO ALTO, CA
Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
Other Events
Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
Preliminary Unaudited Q4 and Full Year 2025 Results
Reports Third Quarter 2025 Financial Results and Business Updates
Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
BridgeBio's Positive Phase 3 Results for BBP-418 in LGMD2I/R9
Reports Second Quarter 2025 Financial Results and Business Updates
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Confidential Treatment Order